Fig. 3From: Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective studyOverall survival rate of 404 patients within 9-year follow-up. The 5-year and 8-year survival rates 90.4% and 88.9%, respectivelyBack to article page